The Role of microRNAs in Development of Colitis-Associated Colorectal Cancer

Colorectal cancer (CRC) is the third most deadly cancer worldwide, and inflammatory bowel disease (IBD) is one of the critical factors in CRC carcinogenesis. IBD is responsible for an unphysiological and sustained chronic inflammation environment favoring the transformation. MicroRNAs (miRNAs) belong to a class of highly conserved short single-stranded segments (18–25 nucleotides) non-coding RNA and have been extensively discussed in both CRC and IBD. However, the role of miRNAs in the development of colitis-associated CRC (CAC) is less clear. The aim of this review is to summarize the major upregulated (miR-18a, miR-19a, miR-21, miR-31, miR-155 and miR-214) and downregulated (miR-124, miR-193a-3p and miR-139-5p) miRNAs in CAC, and their roles in genes’ expression modulation in chronic colonic-inflammation-induced carcinogenesis, including programmed cell-death pathways. These miRNAs dysregulation could be applied for early CAC diagnosis, to predict therapy efficacy and for precision treatment.

[1]  T. Yau,et al.  Fecal microbiota transplantation for recurrent Clostridioides difficile infection associates with functional alterations in circulating microRNAs. , 2021, Gastroenterology.

[2]  H. Fan,et al.  MiR-155 contributes to intestinal barrier dysfunction in DSS-induced mice colitis via targeting HIF-1α/TFF-3 axis , 2020, Aging.

[3]  T. Yau,et al.  Non-Invasive Colorectal Cancer Screening: An Overview , 2020, Gastrointestinal Tumors.

[4]  Sherien M. El-Daly,et al.  Differential expression of miRNAs regulating NF-κB and STAT3 crosstalk during colitis-associated tumorigenesis. , 2019, Molecular and cellular probes.

[5]  Yanqin Sun,et al.  MicroRNA-34a suppresses the invasion and migration of colorectal cancer cells by enhancing EGR1 and inhibiting vimentin , 2019, Experimental and therapeutic medicine.

[6]  C. Pérez-Plasencia,et al.  Crosstalk Between Long Non-coding RNAs, Micro-RNAs and mRNAs: Deciphering Molecular Mechanisms of Master Regulators in Cancer , 2019, Front. Oncol..

[7]  T. Yau,et al.  Faecal microRNAs as a non-invasive tool in the diagnosis of colonic adenomas and colorectal cancer: A meta-analysis , 2019, Scientific Reports.

[8]  C. Lengner,et al.  MicroRNA-31 Reduces Inflammatory Signaling and Promotes Regeneration in Colon Epithelium, and Delivery of Mimics in Microspheres Reduces Colitis in Mice. , 2019, Gastroenterology.

[9]  Fangfang Guo,et al.  CCAT1 lncRNA Promotes Inflammatory Bowel Disease Malignancy by Destroying Intestinal Barrier via Downregulating miR-185-3p. , 2019, Inflammatory bowel diseases.

[10]  Gilles Wainrib,et al.  Colonic MicroRNA Profiles, Identified by a Deep Learning Algorithm, That Predict Responses to Therapy of Patients With Acute Severe Ulcerative Colitis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  T. Yau.  Precision treatment in colorectal cancer: Now and the future , 2019, JGH open : an open access journal of gastroenterology and hepatology.

[12]  N. Zhang,et al.  Faecal microRNA as a biomarker of the activity and prognosis of inflammatory bowel diseases. , 2018, Biochemical and biophysical research communications.

[13]  C. Peng,et al.  Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation , 2018, Front. Endocrinol..

[14]  P. Malfertheiner,et al.  Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases. , 2018, Inflammatory bowel diseases.

[15]  Junfeng Zhang,et al.  PIAS3-mediated feedback loops promote chronic colitis-associated malignant transformation , 2018, Theranostics.

[16]  J. Collins,et al.  MicroRNA-31 and MicroRNA-155 Are Overexpressed in Ulcerative Colitis and Regulate IL-13 Signaling by Targeting Interleukin 13 Receptor α-1 , 2018, Genes.

[17]  Yan Ding,et al.  Inhibition of ATG12-mediated autophagy by miR-214 enhances radiosensitivity in colorectal cancer , 2018, Oncogenesis.

[18]  C. Ishioka,et al.  microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer , 2017, BMC Cancer.

[19]  Yuan Yin,et al.  Long non-coding RNA LINC00152 promotes cell proliferation, metastasis, and confers 5-FU resistance in colorectal cancer by inhibiting miR-139-5p , 2017, Oncogenesis.

[20]  R. Amini,et al.  Involvement of miR-155/FOXO3a and miR-222/PTEN in acquired radioresistance of colorectal cancer cell line , 2017, Japanese Journal of Radiology.

[21]  Zhaoyuan Liu,et al.  Conditional knockout of microRNA-31 promotes the development of colitis associated cancer. , 2017, Biochemical and biophysical research communications.

[22]  Wei Li,et al.  The relationship between microRNAs and the STAT3-related signaling pathway in cancer , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[23]  M. Bissonnette,et al.  miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis–Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD , 2017, Clinical Cancer Research.

[24]  T. Wang,et al.  miR-19a promotes colitis-associated colorectal cancer by regulating tumor necrosis factor alpha-induced protein 3-NF-κB feedback loops , 2017, Oncogene.

[25]  Hong Yu,et al.  Decreased expression of miR-193a-3p is associated with poor prognosis in colorectal cancer , 2017, Oncology letters.

[26]  Yan Shi,et al.  MicroRNA 301A Promotes Intestinal Inflammation and Colitis-Associated Cancer Development by Inhibiting BTG1. , 2017, Gastroenterology.

[27]  Xi Chen,et al.  miR-19a promotes colorectal cancer proliferation and migration by targeting TIA1 , 2017, Molecular Cancer.

[28]  Lei Ma,et al.  MicroRNA-155 promotes the pathogenesis of experimental colitis by repressing SHIP-1 expression , 2017, World journal of gastroenterology.

[29]  Yili Yang,et al.  Nicotine protects against DSS colitis through regulating microRNA-124 and STAT3 , 2017, Journal of Molecular Medicine.

[30]  H. Thorlacius,et al.  MiR-155-5p positively regulates CCL17-induced colon cancer cell migration by targeting RhoA , 2017, Oncotarget.

[31]  R. Maruyama,et al.  EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics , 2017, Oncotarget.

[32]  K. Okazaki,et al.  Downregulation of MicroRNA-21 in Colonic CD3+ T Cells in UC Remission , 2016, Inflammatory bowel diseases.

[33]  J. Zhang,et al.  The signaling axis of microRNA-31/interleukin-25 regulates Th1/Th17-mediated inflammation response in colitis , 2016, Mucosal Immunology.

[34]  L. Liang,et al.  The FOXD3/miR-214/MED19 axis suppresses tumour growth and metastasis in human colorectal cancer , 2016, British Journal of Cancer.

[35]  A. Poprach,et al.  Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients. , 2016, Anticancer research.

[36]  Apostolos Papalois,et al.  The TNBS-induced colitis animal model: An overview , 2016, Annals of medicine and surgery.

[37]  D. Karunagaran,et al.  MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells , 2016, British Journal of Cancer.

[38]  Yuan Yin,et al.  miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1. , 2016, Pathology, research and practice.

[39]  C. Chakraborty,et al.  Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges. , 2016, Current drug metabolism.

[40]  Ye-chun Xu,et al.  miR-139-5p Inhibits the Epithelial-Mesenchymal Transition and Enhances the Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating BCL2 , 2016, Scientific Reports.

[41]  P. Ji,et al.  Aberrant DNA Methylation: Implications in Racial Health Disparity , 2016, PloS one.

[42]  Yvonne Will,et al.  Drug Discovery Toxicology: From Target Assessment to Translational Biomarkers , 2016 .

[43]  M. Pittman,et al.  Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers. , 2016, Gastroenterology.

[44]  Jianwen Liu,et al.  Targeted deletion of miR‐139‐5p activates MAPK, NF‐κB and STAT3 signaling and promotes intestinal inflammation and colorectal cancer , 2016, The FEBS journal.

[45]  M. Nagarkatti,et al.  MicroRNA-155 deletion promotes tumorigenesis in the azoxymethane-dextran sulfate sodium model of colon cancer. , 2016, American journal of physiology. Gastrointestinal and liver physiology.

[46]  R. Maruyama,et al.  The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway , 2016, Oncotarget.

[47]  Jianwen Liu,et al.  The loss of MiR-139-5p promotes colitis-associated tumorigenesis by mediating PI3K/AKT/Wnt signaling. , 2015, The international journal of biochemistry & cell biology.

[48]  Jun Yu,et al.  microRNA-20a in human faeces as a non-invasive biomarker for colorectal cancer , 2015, Oncotarget.

[49]  D. Iliopoulos,et al.  MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice. , 2015, Gastroenterology.

[50]  Kazuhiro Yoshida,et al.  Positive feedback of DDX6/c-Myc/PTB1 regulated by miR-124 contributes to maintenance of the Warburg effect in colon cancer cells. , 2015, Biochimica et biophysica acta.

[51]  Lei Wang,et al.  Hsa-miR-19a is associated with lymph metastasis and mediates the TNF-α induced epithelial-to-mesenchymal transition in colorectal cancer , 2015, Scientific Reports.

[52]  Hiromu Suzuki,et al.  Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer , 2015, Annals of Surgical Oncology.

[53]  Y. Akao,et al.  MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. , 2015, Cancer letters.

[54]  M. Gazouli,et al.  miRNA-26b Overexpression in Ulcerative Colitis-associated Carcinogenesis , 2015, Inflammatory bowel diseases.

[55]  Xiao Han,et al.  Up-regulated miR-155-5p promotes cell proliferation, invasion and metastasis in colorectal carcinoma. , 2015, International journal of clinical and experimental pathology.

[56]  Yongzhi Yang,et al.  Novel evidence for an oncogenic role of microRNA-21 in colitis-associated colorectal cancer , 2015, Gut.

[57]  E. Novellino,et al.  Antioxidant peptides from "Mozzarella di Bufala Campana DOP" after simulated gastrointestinal digestion: In vitro intestinal protection, bioavailability, and anti-haemolytic capacity , 2015 .

[58]  P. Brun,et al.  MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis , 2015, Experimental & Molecular Medicine.

[59]  X. Chen,et al.  MicroRNA-193a-3p Reduces Intestinal Inflammation in Response to Microbiota via Down-regulation of Colonic PepT1* , 2015, The Journal of Biological Chemistry.

[60]  Junfeng Zhang,et al.  C/EBP-β-activated microRNA-223 promotes tumour growth through targeting RASA1 in human colorectal cancer , 2015, British Journal of Cancer.

[61]  J. Pekow,et al.  The emerging role of miRNAs in inflammatory bowel disease: a review , 2015, Therapeutic advances in gastroenterology.

[62]  V. Baumann,et al.  miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. , 2014, Future medicinal chemistry.

[63]  Hiromu Suzuki,et al.  MicroRNA‐31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions , 2014, International journal of cancer.

[64]  Yong Huang,et al.  Divergent Influence of MicroRNA-21 Deletion on Murine Colitis Phenotypes , 2014, Inflammatory bowel diseases.

[65]  D. Taub,et al.  miR‐155 deficiency protects mice from experimental colitis by reducing T helper type 1/type 17 responses , 2014, Immunology.

[66]  Jun Yu,et al.  microRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma , 2014, British Journal of Cancer.

[67]  Hiromu Suzuki,et al.  MicroRNA-31 expression in colorectal serrated pathway progression. , 2014, World journal of gastroenterology.

[68]  Yuan Yin,et al.  MiR-139-5p inhibits migration and invasion of colorectal cancer by downregulating AMFR and NOTCH1 , 2014, Protein & Cell.

[69]  Hiromu Suzuki,et al.  Analysis of DNA Methylation in Bowel Lavage Fluid for Detection of Colorectal Cancer , 2014, Cancer Prevention Research.

[70]  Fenghua Wang,et al.  Identification of MicroRNA‐214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression , 2014, Hepatology.

[71]  S. Horita,et al.  Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4 , 2014, Cancer medicine.

[72]  R. Lai,et al.  STAT3 in Cancer—Friend or Foe? , 2014, Cancers.

[73]  Jun Yu,et al.  microRNA-139-5p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer , 2014, Molecular Cancer.

[74]  F. Rojo,et al.  Downregulation of miR-214 is specific of liver metastasis in colorectal cancer and could play a role determining the metastatic niche , 2014, International Journal of Colorectal Disease.

[75]  Hiromu Suzuki,et al.  Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. , 2014, Carcinogenesis.

[76]  Min Guo,et al.  MicroRNA-155 Is Involved in the Pathogenesis of Ulcerative Colitis by Targeting FOXO3a , 2014, Inflammatory bowel diseases.

[77]  Jun Yu,et al.  Identification of microRNA-135b in Stool as a Potential Noninvasive Biomarker for Colorectal Cancer and Adenoma , 2014, Clinical Cancer Research.

[78]  Yu Hu,et al.  The Pro-Apoptotic Role of the Regulatory Feedback Loop between miR-124 and PKM1/HNF4α in Colorectal Cancer Cells , 2014, International journal of molecular sciences.

[79]  Y. Zhong,et al.  MicroRNA-31 contributes to colorectal cancer development by targeting factor inhibiting HIF-1α (FIH-1) , 2014, Cancer biology & therapy.

[80]  S. Woo,et al.  Comparison of experimental mouse models of inflammatory bowel disease. , 2014, International journal of molecular medicine.

[81]  D. Rubin,et al.  Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[82]  P. Treuting,et al.  Characterization of Dextran Sodium Sulfate-Induced Inflammation and Colonic Tumorigenesis in Smad3 −/− Mice with Dysregulated TGFβ , 2013, PloS one.

[83]  M. Fabbri,et al.  MicroRNAs and other non-coding RNAs as targets for anticancer drug development , 2013, Nature Reviews Drug Discovery.

[84]  D. Iliopoulos,et al.  MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. , 2013, Gastroenterology.

[85]  Xiuchao Wang,et al.  Downregulation of microRNA-214 and overexpression of FGFR-1 contribute to hepatocellular carcinoma metastasis. , 2013, Biochemical and biophysical research communications.

[86]  Ying Wang,et al.  MiR-124 Suppresses Growth of Human Colorectal Cancer by Inhibiting STAT3 , 2013, PloS one.

[87]  Yongzhi Yang,et al.  MicroRNA-21 Knockout Improve the Survival Rate in DSS Induced Fatal Colitis through Protecting against Inflammation and Tissue Injury , 2013, PloS one.

[88]  Zhihui Liu,et al.  Role of miR-19a targeting TNF-α in mediating ulcerative colitis , 2013, Scandinavian journal of gastroenterology.

[89]  A. Duval,et al.  Overexpression of microRNAs-155 and 21 targeting mismatch repair proteins in inflammatory bowel diseases. , 2013, Carcinogenesis.

[90]  X. Chen,et al.  MicroRNA-31 Activates the RAS Pathway and Functions as an Oncogenic MicroRNA in Human Colorectal Cancer by Repressing RAS p21 GTPase Activating Protein 1 (RASA1)* , 2013, The Journal of Biological Chemistry.

[91]  Yu Hu,et al.  miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect. , 2012, Oncology reports.

[92]  Jianwen Liu,et al.  MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. , 2012, Biochemical pharmacology.

[93]  V. Poli,et al.  PKM2, STAT3 and HIF-1α , 2012, JAK-STAT.

[94]  L. Peyrin-Biroulet,et al.  Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[95]  N. Crawford,et al.  Differential MicroRNA expression tracks neoplastic progression in inflammatory bowel disease‐associated colorectal cancer , 2012, Human mutation.

[96]  Dimitrios Iliopoulos,et al.  Neurotensin signaling activates microRNAs-21 and -155 and Akt, promotes tumor growth in mice, and is increased in human colon tumors. , 2011, Gastroenterology.

[97]  S. Ben-Horin,et al.  Review article: loss of response to anti‐TNF treatments in Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.

[98]  Jennifer M. Carr,et al.  Differential Expression of MicroRNAs in Tumors from Chronically Inflamed or Genetic (APCMin/+) Models of Colon Cancer , 2011, PloS one.

[99]  M. Wasik,et al.  Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA , 2011, Oncogene.

[100]  T. Muto,et al.  Ulcerative colitis‐associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: A nationwide Japanese study , 2011, Inflammatory bowel diseases.

[101]  J. Manley,et al.  Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. , 2010, Cancer research.

[102]  J. Turkson,et al.  A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction , 2010, Aging.

[103]  Kevin Struhl,et al.  STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. , 2010, Molecular cell.

[104]  T. Dassopoulos,et al.  Dynamic changes in the expression of MicroRNA‐31 during inflammatory bowel disease‐associated neoplastic transformation , 2010, Inflammatory bowel diseases.

[105]  T. Elton,et al.  MiR-155 Induction by F. novicida but Not the Virulent F. tularensis Results in SHIP Down-Regulation and Enhanced Pro-Inflammatory Cytokine Response , 2009, PloS one.

[106]  S. Spechler,et al.  Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer , 2009, Nature Reviews Gastroenterology &Hepatology.

[107]  Manuel A. S. Santos,et al.  MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells , 2009, Proceedings of the National Academy of Sciences.

[108]  K. Sugimoto.  Role of STAT3 in inflammatory bowel disease. , 2008, World journal of gastroenterology.

[109]  N. Rajewsky,et al.  Widespread changes in protein synthesis induced by microRNAs , 2008, Nature.

[110]  J. Nemunaitis,et al.  Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? , 2008, Cancer Gene Therapy.

[111]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[112]  George A Calin,et al.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. , 2008, JAMA.

[113]  S. Itzkowitz,et al.  Cancer in inflammatory bowel disease. , 2008, World journal of gastroenterology.

[114]  David Baltimore,et al.  MicroRNA-155 is induced during the macrophage inflammatory response , 2007, Proceedings of the National Academy of Sciences.

[115]  J. Turner,et al.  Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. , 2006, The American journal of pathology.

[116]  H. Sørensen,et al.  Survival After Colorectal Cancer in Patients with Ulcerative Colitis: A Nationwide Population-Based Danish Study , 2006, The American Journal of Gastroenterology.

[117]  L. Melton,et al.  Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. , 2006, Gastroenterology.

[118]  K R Abrams,et al.  Meta‐analysis: colorectal and small bowel cancer risk in patients with Crohn's disease , 2006, Alimentary pharmacology & therapeutics.

[119]  M. Neurath,et al.  Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer , 2005, Clinical reviews in allergy & immunology.

[120]  P. Dentelli,et al.  Signal Transducers and Activators of Transcription 3 Signaling Pathway: An Essential Mediator of Inflammatory Bowel Disease and Other Forms of Intestinal Inflammation , 2005, Inflammatory bowel diseases.

[121]  P. Kostenuik,et al.  CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin , 2004, Gut.

[122]  Alastair Forbes,et al.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. , 2004, Gastroenterology.

[123]  K. Abrams,et al.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis , 2001, Gut.

[124]  E. Kliewer,et al.  Cancer risk in patients with inflammatory bowel disease , 2001, Cancer.

[125]  F. Cominelli,et al.  Lessons from genetically engineered animal models XI. Novel mouse models to study pathogenic mechanisms of Crohn's disease. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[126]  M. Leach,et al.  Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. , 1996, The Journal of clinical investigation.

[127]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[128]  C. Trautwein,et al.  Faecal micro-RNAs in inflammatory bowel diseases. , 2019, Journal of Crohn's & colitis.

[129]  J. Vider,et al.  Clinical and biological significance of miR-193a-3p targeted KRAS in colorectal cancer pathogenesis. , 2018, Human pathology.

[130]  S. Nordling,et al.  Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: A case–control observational study based on registry data , 2014, International journal of cancer.

[131]  Y. Surh,et al.  The Azoxymethane Plus Dextran Sulfate Sodium-Induced Mouse Colon Cancer Model for the Study of Dietary Chemoprevention of Inflammation-Associated Carcinogenesis , 2014 .

[132]  O. Nielsen,et al.  Tumor necrosis factor inhibitors for inflammatory bowel disease. , 2013, The New England journal of medicine.

[133]  E. Szigethy,et al.  Inflammatory bowel disease. , 2011, Pediatric clinics of North America.

[134]  L. Bartoli,et al.  STAT 3 ‐ mediated metabolic switch is involved in tumour transformation and STAT 3 addiction , 2010 .

[135]  E. Mizoguchi.  Role of STAT3 in inflammatory bowel disease , 2009 .